APTITUDE HEALTH®

EPICS

EPICS Conference Coverage: SABCS 2021 – Focus on Breast Cancer

December 14, 2021

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
December 14, 2021



DISEASE STATE AND DATA PRESENTATIONS by key experts

INSIGHT REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in breast cancer

- 5 from US
- 2 from Europe

BREAST CANCER-SPECIFIC DISCUSSIONS on therapeutic advances and their application into clinical decision-making

Panel Consisting of 5 US and 2 European Breast Cancer Experts

EPICS

Mark Pegram, MD
Stanford Cancer Institute

Hope Rugo, MD, FASCO
UCSF Helen Diller Family
Comprehensive Cancer Center

CHAIR:
Adam Brufsky, MD, PhD
University of Pittsburgh
School of Medicine

Joyce A. O'Shaughnessy, MD
Baylor Scott & White Charles A.
Sammons Cancer Center

Mary Cianfrocca, DO, MBA
City of Hope

Miguel Martín, MD
Complutense University

Javier Cortes, MD, PhD
Vall d'Hebron University Hospital

APTITUDE HEALTH®

Meeting Agenda

EPICS

Time (EST)	Topic	Speaker/Moderator
10.00 AM – 10.10 AM	Welcome, Introductions, and Meeting Objectives	Adam Brufsky, MD, PhD
10.10 AM – 10.20 AM	Advancing Therapy for Metastatic HER2+ Breast Cancer	Javier Cortes, MD, PhD
10.20 AM – 10.40 AM	Discussion and Key Takeaways	
10.40 AM – 10.50 AM	Other Novel Endocrine Strategies for ER+ Breast Cancer	Miguel Martín, MD, PhD
10.50 AM – 11.05 AM	Discussion and Key Takeaways	
11.05 AM – 11.15 AM	ER+ Breast Cancer – Targeting CDKs	Hope Rugo, MD, FASCO
11.15 AM – 11.35 AM	Discussion and Key Takeaways	
11.35 AM – 11.45 AM	***Break***	
11.45 AM – 11.55 AM	Targeting Triple-Negative Breast Cancer	Joyce O'Shaughnessy, MD
11.55 AM – 12.10 PM	Discussion and Key Takeaways	
12.10 PM – 12.20 PM	Biomarkers and Tailored Therapy	Mary Cianfrocca, DO, MBA
12.20 PM – 12.35 PM	Discussion and Key Takeaways	
12.35 PM – 12.40 PM	Other Novel Therapeutic Approaches for Breast Cancer	Mark Pegram, MD
12.40 PM – 12.55 PM	Discussion and Key Takeaways	
12.55 PM – 1.00 PM	Closing Remarks and Adjourn	Adam Brufsky, MD, PhD

APTITUDE HEALTH®

EPICS

Congress Highlights

ER+ Breast Cancer – Targeting CDKs

Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

Gnant, et al. 2021, SABCS GS1-07

EPICS

STUDY POPULATION

PRIMARY ENDPOINT: iDFS

Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in HR+/HER2- advanced breast cancer

Carey, et al. 2021, SABCS GS2-00

EPICS

DESIGN

INTRINSIC SUBTYPE WAS PROGNOSTIC FOR OS

Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer

O'Shaughnessy, et al. 2021, SABCS GS2-01

EPICS

STUDY POPULATION

EXPLORATORY OS ANALYSES – BONE-ONLY METS

Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating *ESR1* mutation in HR+ HER2- mBC: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

Bidard, et al. 2021, SABCS GS3-05

EPICS

STUDY POPULATION

PFS AFTER RANDOMIZATION

Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Coombes, et al. 2021, SABCS GS3-10

EPICS

STUDY POPULATION

CLINICAL BENEFIT RATE

APTITUDE HEALTH®

EPICS

Key Insights

ER+ Breast Cancer – Targeting CDKs

Experts Debated the Reasons for the Differences in Outcomes Between the Adjuvant CDK4/6 Inhibitor Trials

EPICS

PALLAS VS MONARCH-E

Experts Discussed the Impact of the Subset Analyses From the MONALEESA Trials

EPICS

MONALEESA-2 SUBGROUPS

Results of the MONALEESA-2 metastatic site subset analyses suggest that all subgroups experience an OS benefit from ribociclib in

Experts Discussed the Future Potential of Investigational Strategies Involving CDK Inhibitors

EPICS

PADA-1

Results from the PADA-1 trial showed that for patients who developed an *ESR-1* mutation while receiving an aromatase inhibitor,

APTITUDE HEALTH®

EPICS

Congress Highlights

Other Novel Endocrine Strategies for ER+ Breast Cancer

A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer

Xu, et al. 2021, SABCS GS1-06

EPICS

STUDY POPULATION

PROGRESSION-FREE SURVIVAL

Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results EMERALD phase 3 trial

Bardia, et al. 2021, SABCS GS2-02

EPICS

STUDY POPULATION

PFS: ELACESTRANT VS FULVESTRANT

Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomized trials

Bradley, et al. 2021, SABCS GS2-04

EPICS

STUDY POPULATION

RECURRENCE RATES

Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

Regan, et al. 2021, SABCS GS2-05

EPICS

STUDY POPULATION

SOFT: PRIOR CHEMOTHERAPY COHORT

APTITUDE HEALTH®

EPICS

Key Insights

Other Novel Endocrine Strategies for ER+ Breast Cancer

Experts Assessed Investigational Approaches for HR+ mBC

EPICS

ELACESTRANT

Experts were impressed with the results of the EMERALD trial showing superior

Experts Discussed Endocrine Therapies for Premenopausal Patients With Early Stage HR+ Breast Cancer

EPICS

META-ANALYSIS AND SOFT/TEXT DATA

The meta-analysis of 4 trials comparing adjuvant therapy with OFS with either

APTITUDE HEALTH®

EPICS

Congress Highlights

Advancing Therapy for Metastatic HER2+ Breast Cancer

Trastuzumab deruxtecan vs trastuzumab emtansine in HER2+ mBC: subgroup analyses from DESTINY-Breast03

Hurvitz, et al. 2021, SABCS GS3-01

EPICS

STUDY POPULATION

PFS IN PATIENTS WITH STABLE/TREATED BRAIN METS

Updated OS results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine for HER2+ mBC

Xu, et al. 2021, SABCS GS3-02

EPICS

STUDY POPULATION

OVERALL SURVIVAL

Results from phase 2 TBCRC049 study: Tucatinib-trastuzumab-capecitabine for leptomeningeal metastasis in HER2+ breast cancer

Murthy, et al. 2021, SABCS PD4-02

EPICS

STUDY POPULATION

SURVIVAL AND PROGRESSION

Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ mBC with brain metastases (HER2CLIMB)

Lin, et al. 2021, SABCS PD4-04

EPICS

STUDY POPULATION

[illegible]

OVERALL SURVIVAL

[illegible]

Preliminary results from DEBBRAH: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing mBC with CNS involvement

Vaz Batista, et al. 2021, SABCS PD4-06

EPICS

STUDY POPULATION

ANTITUMOR ACTIVITY

Intracranial efficacy of tucatinib, palbociclib and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases

Shagisultanova, et al. 2021, SABCS P1-18-26

EPICS

STUDY POPULATION

TIME ON STUDY

Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + CTX in patients with HER2+ mBC: Final OS analysis

Rugo, et al. 2021, SABCS PD8-01

EPICS

STUDY POPULATION

OVERALL SURVIVAL

APTITUDE HEALTH®

EPICS

Key Insights

Advancing Therapy for Metastatic HER2+ Breast Cancer

Experts Discussed Treatments for Patients With HER2+ CNS Metastases

EPICS

TRASTUZUMAB DERUXTECAN

The activity of trastuzumab deruxtecan (T-DXd) against stable brain metastases observed in the DESTINY-Breast03 trial is considered

Experts Discussed Currently Approved and Investigational Agents for HER2+ Breast Cancer

EPICS

NERATINIB

Neratinib is still being used in the extended adjuvant setting

MARGETUXIMAB

Although there was no OS advantage for margetuximab in the

APTITUDE HEALTH®

EPICS

Congress Highlights

Targeting Triple-Negative Breast Cancer

Final results of KEYNOTE-355: Pembrolizumab + chemotherapy for previously untreated mTNBC

Cortes, et al. 2021, SABCS GS1-02

EPICS

STUDY POPULATION

OVERALL SURVIVAL BY CPS SCORE

KEYNOTE-522: Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembro for early TNBC: EFS sensitivity and subgroup analyses

Schmid, et al. 2021, SABCS GS1-01

EPICS

STUDY POPULATION

EFS SUBGROUP ANALYSES

Quality of life results from OlympiA: Adjuvant olaparib in patients with high-risk gBRCA1/2 mutated HER-2 negative early breast cancer

Ganz, et al. 2021, SABCS GS4-09

EPICS

STUDY POPULATION

FACIT-FATIGUE CHANGE FROM BASELINE

APTITUDE HEALTH®

EPICS

Key Insights

Targeting Triple-Negative Breast Cancer

Experts Discussed Treatments for Patients With Early Stage TNBC and Residual Disease After Neoadjuvant Therapy

EPICS

OLYMPIA

Experts Discussed Pembrolizumab for Early Stage and Metastatic TNBC

EPICS

KEYNOTE-522

The subset analyses of the KEYNOTE-522 trial confirmed that all subsets of patients benefited from the addition of pembrolizumab to

APTITUDE HEALTH®

EPICS

Congress Highlights

Biomarkers and Tailored Therapy

Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST

Andre, et al. 2021, SABCS GS1-10

EPICS

STUDY POPULATION AND DESIGN

ESCAT CLASSIFICATION FRAMEWORK

APTITUDE HEALTH®

cTRAK TN: Utilising ctDNA mutation tracking to detect MRD and trigger intervention in patients with moderate and high risk early stage TNBC

Turner, et al. 2021, SABCS GS3-06

EPICS

STUDY POPULATION

OBSERVATION GROUP – LEAD TIME TO RECURRENCE

RxPONDER Update: Endocrine therapy +/- chemotherapy for HR+/HER2- BC with 1–3 positive lymph nodes with an RS ≤25

Kalinsky, et al. 2021, SABCS GS2-07

EPICS

STUDY POPULATION

PREMENOPAUSAL SUBSET ANALYSES

APTITUDE HEALTH®

EPICS

Key Insights

Biomarkers and Tailored Therapy

Experts Discussed Results From Trials Exploring the Use of Molecular Testing in Breast Cancer

EPICS

SAFIR02

The SAFIR02 trial evaluated whether matching targeted therapies to molecular alterations compared with standard chemotherapy in

Experts Reviewed Updated Results From the RxPONDER Trial

EPICS

RxPONDER

The Oncotype DX Recurrence Score (RS) is perceived to be useful in the

APTITUDE HEALTH®

EPICS

Congress Highlights

Other Novel Therapeutic Approaches for Breast Cancer

Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

Krop, et al. 2021, SABCS GS1-05

EPICS

CCTG MA.32, a phase III trial of adjuvant metformin vs placebo in early breast cancer: Primary efficacy analysis

Goodwin, et al. 2021, SABCS GS1-08

EPICS

Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative mBC

Barroso-Sousa, et al. 2021, SABCS GS2-10

EPICS

Neratinib + fulvestrant + trastuzumab for HR+, *HER2*-mutant mBC and neratinib + trastuzumab for TNBC: SUMMIT trial updates

Jhaveri, et al. 2021, SABCS GS4-10

EPICS

APTITUDE HEALTH®

EPICS

Key Insights

Other Novel Therapeutic Approaches for Breast Cancer

Experts Assessed Phase I Data With Novel Agents for mBC

EPICS

DATOPOTAMAB DERUXTECAN

Experts Discussed Data From Trials in *HER2*+ or *HER2*-Mutated Breast Cancer

EPICS

SUMMIT